1833 related articles for article (PubMed ID: 16011514)
1. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
2. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
4. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
Asnagli H; Schmitt-Verhulst AM; Guimezanes A
J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune hepatic inflammation by vaccination of mice with dendritic cells loaded with well-differentiated hepatocellular carcinoma cells and administration of interleukin-12.
Tamaki S; Homma S; Enomoto Y; Komita H; Zeniya M; Ohno T; Toda G
Clin Immunol; 2005 Dec; 117(3):280-93. PubMed ID: 16246626
[TBL] [Abstract][Full Text] [Related]
6. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
7. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
8. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
10. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
13. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 up-regulates perforin- and Fas-mediated lymphokine-activated killer activity by intestinal intraepithelial lymphocytes.
Ebert EC
Clin Exp Immunol; 2004 Nov; 138(2):259-65. PubMed ID: 15498035
[TBL] [Abstract][Full Text] [Related]
15. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells.
Williams NS; Engelhard VH
J Immunol; 1997 Sep; 159(5):2091-9. PubMed ID: 9278294
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
[TBL] [Abstract][Full Text] [Related]
18. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
19. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
[TBL] [Abstract][Full Text] [Related]
20. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
